07.09.2021 • News

Invista Beefing up PA Output in Shanghai

Invista Nylon Chemicals (China), subsidiary of Wichita, Kansas-based US polyamide giant Invista, has announced a major expansion of its PA 6.6 capacity in China’s Shanghai Chemical Industry Park (SCIP), which It said will strengthen its integrated production chain in the People’s Republic.

The company’s Chinese arm plans to invest $ 230 million in two production lines at the Shanghai site, thereby more than doubling its output capability from currently 190,000 t/y to 400,000 t/y. Some 40,000 t/y of new capacity was added in late 2020. Work on the massive expansion is due to begin at the beginning of 2022, with start-up planned for spring 2024.

Invista’s latest investment in the chemical park goes hand-in-hand with an upstream project that calls for adding 400,000 t/ of adiponitrile (ADN) capability) by the beginning of 2021. This new facility will feed the site’s 215,000 t/y production of nylon intermediate hexamethylenediamine (HMD).

Supporting the buildup, Invista said, is the projected compounded annual growth rate of 4% in Chinese demand for PA 6.6 – about twice that forecast for the market globally. The company noted also that the enhanced capacity will allow it to more quickly respond to growing demand in its Asian main markets of engineering plastics and apparel.

The world’s largest producer of polyamide, which owns the rights to the Nylon trademark, calculates additionally that Chinese demand for PA products will account for more than half the total production and consumption n in the Asia-Pacific region altogether.

Author: Dede Williams, Freelance Journalist

 

In a move to strengthen its integrated production chain, US nylon giant Invista...
In a move to strengthen its integrated production chain, US nylon giant Invista is investing $230 million in two new PA 6.6 production lines its Shanghai, China, site, more than doubling capacity from 190,000 t/y to 400,000 t/y. The expansion is due on stream in spring 2024. (c) Invista

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.